単一チャンバー型ペースメーカーの世界市場-2024～2031年

概要

単一チャンバー型ペースメーカーの世界市場は2023年に22億米ドルに達し、2031年には27億7,000万米ドルに達すると予測され、予測期間2024年にはCAGR 3.0%で成長する見込みです。

単一チャンバー型ペースメーカーは、心房または心室という1つの心室に電気インパルスを供給する装置です。このタイプのペースメーカーは、心拍数が遅い（徐脈）、または心臓の適切な速度を維持する能力が制限される他のリズム障害に苦しむほとんどの患者に最も有用です。このタイプのペースメーカーは、パルス発生器（回路を備えた電池）と、目的の心室に電気信号を送るためのリード線から構成されています。臨床医は、不整脈のために複数の心室間の同期を必要としない患者には、単心室システムは複心室システムや両心室システムよりも単純な装置であると考えています。最小侵襲技術により、信頼性が高く費用対効果の高い心拍管理が実現します。

市場力学：

促進要因と抑制要因

心血管疾患の有病率の上昇

不整脈、特に徐脈性不整脈や心ブロックなどの疾患の増加は、単一チャンバー型ペースメーカー市場の世界的拡大に大きく寄与しています。高齢者の増加は、高齢者が心臓のリズムに関連した障害をより多く患うため、心血管疾患の発生率をさらに増加させる。

リズムに関連する心臓疾患の効果的な管理は、必要とする患者に心臓機能を提供するために不可欠となった単室ペースメーカーによって可能となりました。また、心臓疾患の早期診断と治療に対する患者の意識の高まりも、ペースメーカーの普及に拍車をかけた。たいていの場合、単室ペースメーカは、資源の乏しい地域において、効果的で信頼性が高く、しかも費用対効果の高い治療を提供するのに十分な単室であり、市場でのシェアを保証しています。

例えば、英国心臓財団によると、心血管系疾患は依然として世界中の男女の死亡原因の第一位です。2023年の世界人口は80億人で、そのうち約6,200億人が心臓や血管の病気に苦しんでいます。毎年、世界中で約600億人が心臓や循環器系の病気と診断されます。患者の13人に1人が心臓や循環器の病気にかかっていると言われています。心血管疾患は世界の死亡原因のおよそ3人に1人を占めており、2021年には世界で205億人以上が死亡し、これは毎日5万6,000人、または約1.5秒に1人の割合で命が失われていることになります。

先進的代替医療

ペースメーカーは、より広範な心臓リズム管理のために開発されました。これらのデバイスは心臓の複数の部屋に電気インパルスを同期させるもので、複雑な不整脈や心不全のある患者にとってより有益であることが証明されています。したがって、医療プロバイダーは、特に医療予算の多い新興国市場では、おそらく単室ペースメーカーよりも先進的なオプションを好むであると考えられます。

さらに、このようなペースメーカの普及を妨げる他の要因として、植え込みや継続的なペースメーカのメンテナンスにかかる費用が高額になることがあげられます。また、特に資源に乏しい地域の患者やその医師の間では、感染症、リードの脱落、機器の誤作動などの合併症が懸念されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 心血管疾患の罹患率の上昇
• 抑制要因
  • 先進的代替品の入手可能性
• 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 製品タイプ別

• 植込み型単腔ペースメーカー
• 体外式単腔ペースメーカー

第7章 適応症別

• 徐脈
• 心房細動
• ハートブロック
• 副鼻腔炎症候群
• その他

第8章 エンドユーザー別

• 病院
• 外来手術センター（ASC）
• 心臓クリニック

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Medtronic
• Boston Scientific Corporation
• Abbott Laboratories
• BIoTronik SE & Co. KG
• MicroPort Scientific Corporation
• LivaNova PLC
• Osypka Medical GmbH
• Lepu Medical Technology
• Oscor Inc
• Shree Pacetronix Ltd

第12章 付録

Overview

The global single-chamber pacemaker market reached US$ 2.20 Billion in 2023 and is expected to reach US$ 2.77 Billion by 2031, growing at a CAGR of 3.0% during the forecast period 2024-2031.

Single-chamber pacemaker is a device that provides electrical impulses to one heart chamber, namely the atrium or the ventricle. This type of pacemaker is most helpful to most patients suffering from slow heart rate (bradycardia) or any other rhythm disorder that limits its ability to maintain an adequate rate in the heart. It comprises a pulse generator-a battery with circuitry-and a lead for electrical signals passing to the chamber of interest. Clinicians consider single-chamber systems simpler devices than dual-chamber or biventricular systems for patients whose rhythm irregularities do not require synchronization between multiple chambers. Minimal-invasive technology provides reliable, cost-effective heart rhythm management.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Cardiovascular Diseases

Rising numbers of arrhythmias, particularly such conditions as bradyarrhythmias or heart block, significantly contribute to the global expansion of the single-chamber pacemaker market. Rising elderly population further increases the incidence of cardiovascular conditions as older adults suffer more from the rhythm-related disorder of the heart.

Effective management of the rhythm-related heart disorders was made possible with single-chamber pacemakers, which became essential in providing heart function to patients in need. They also have been fueled by a greater demand for awareness of a patient's early diagnosis and treatment in cardiac problems. Most times, single-chamber pacemakers are single enough to provide effective and reliable, but cost-effective therapy in resource-strapped regions, guaranteeing their share in the market.

For instance, according to British Heart Foundation, cardiovascular disease remains the leading cause of death in both men and women throughout the world. In the year of 2023 the world's population is 8 billion out of those approximately 620 Billion are suffering from cardiac and vascular illnesses everywhere across the globe. Every year approximately sixty Billion individuals in the globe will be diagnosed with heart or circulatory disease. It has been suggested that one out of every 13 patients has heart or circulatory ailments. Cardiovascular diseases are responsible for roughly 1 out of 3 deaths in the world; these accounted for - over 20.5 Billion deaths worldwide in 2021 - which is 56,000 lost lives every day or almost one every 1 and 1/2 second.

Availability of Advanced Alternatives

pacemakers, for more extensive heart rhythm management. These devices synchronize electrical impulses into several chambers of the heart, which has be proved to be more beneficial for patients with complex arrhythmias or heart failure. Hence, healthcare providers would probably favor advanced options over single-chamber pacemakers, especially in developed economic markets that have higher healthcare budgets.

Moreover, other impediments in the adoption of these devices would be high prices associated with the implantation and ongoing maintenance of the pacemaker where there is a lack of sufficient skilled professionals in some resource-limited areas that lead to constraints in costing. There are also fears of complications such as those of infection, lead dislocation, and malfunction of the devices, particularly among patients and their physicians from resource-constrained settings.

Segment Analysis

The global single-chamber pacemaker market is segmented based on product type, indication, end user, and region.

Product type:

Implantable single-chamber pacemakers segment is expected to dominate the single-chamber pacemaker market share

The implantable single-chamber pacemakers segment holds a major portion of the single-chamber pacemaker market share and is expected to continue to hold a significant portion of the single-chamber pacemaker market share during the forecast period.

An implantable single-chamber pacemaker is a primary source in the single-chamber pacemakers for managing long-term cardiac rhythms with an ideal solution for disorders such as bradycardia and heart block. It is surgically implanted under the skin with a lead connected to either the atrium or ventricle for heart rate regulation. Due to their ability to read and respond to the electrical activity of the heart, they are critical for the patient who requires constant rhythm management. It is mainly a long-term solution for heart rhythm disorders.

The main reason these devices have energy demand is their durability, better extensions, and utility in terms of features such as MRI compatibility and remote monitoring. These devices gained an entry into developed and emerging markets, thus being established as essential in this segment in the single-chamber pacemaker market.

End User:

Hospitals segment is the fastest-growing segment in the single-chamber pacemaker market share

The hospitals segment is the fastest-growing segment in the single-chamber pacemaker market share and is expected to hold the market share over the forecast period.

Hospitals will constitute some of the main areas in terms of the Global Single-Chamber Pacemaker Market: diagnosis, implantation, and follow-up care for pacemaker patients. They provide necessary infrastructure such as specialized cardiac care units and skilled medical personnel, including cardiologists and electrophysiologists, trained to manage pacemaker procedures. Hospitals are often the first point of contact for patients with arrhythmias or other cardiac complaints, triggering early diagnosis and timely intervention.

Furthermore, hospitals propel the advanced technologies and treatment protocols adoption, ensuring that the patients receive the latest pacemaker models enhanced with better functionality. Additionally, hospitals sustain growth in the market by taking part in clinical trials that help advance pacemaker technology and offering training programs that uphold the growth of expertise in the implanting and management of pacemaker devices.

Geographical Analysis

North America is expected to hold a significant position in the Single-Chamber Pacemaker market share

North America holds a substantial position in the Single-Chamber Pacemaker market and is expected to hold most of the market share due to increasing incidences of cardiovascular disorders and new arrhythmias due to research developments, in the wake of a growing elderly population. Highly advanced health care infrastructure, along with greater access to high-end technologies, contribute significantly to the growth of the market. Also, strong healthcare reimbursement policies in countries such as the United States and Canada further make pacemaker therapies more accessible. Continued collaboration on research and development by prominent market players with favourable regulatory approvals can also further boost market growth in this region.

For instance, in July 2023, Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to expand the indication for current-generation INGEVITY Pacing Leads. These are thin wires placed inside the heart and connected to an implantable device and allow conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) in connection with a single- or dual-chamber pacemaker.

Europe is growing at the fastest pace in the Single-Chamber Pacemaker market

Europe holds the fastest pace in the Single-Chamber Pacemaker market and is expected to hold most of the market share.

Europe, a convergence of an aging populace and a rise in lifestyle-related heart problems will drive the Single-Chamber Pacemaker Market's growth. The strong public healthcare systems make countries such as Germany, France, and the UK perfect beneficiaries of the growing market of cardiac care. Ongoing improvements in pacemaker technology, to make more compact devices with greater battery life, also play an influential role. Furthermore, the European Union's efforts in fostering new innovations in medical devices and the presence of well-known international medical-device manufacturers contribute to the growth of the market.

For instance, in July 2023, BIOTRONIK announced FDA approval for its suite of Amvia Edge pacemakers and CRT-Ps, the company's new technology for cardiac rhythm management. Introducing innovative patient-centric clinical solutions, it is also the most efficient automated workflow. Amvia Edge is the market's smallest single-chamber MR conditional pacemaker.

Competitive Landscape

The major global players in the single-chamber pacemaker market include Medtronic, Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Osypka Medical GmbH, Lepu Medical Technology, Oscor Inc, Shree Pacetronix Ltd among others.

Emerging Players

The emerging players in the single-chamber pacemaker market include Medico, EPMed, CureMetrix, Zoll Medical and among others.

Key Developments

• In November 2024, Abbott recently announced the launch of the AVEIR VR single-chamber ventricular leadless pacemaker, meant for treating patients with slow heart rhythms in India. This pacemaker has already received approval from the Central Drugs Standard Control Organization (CDSCO) in India. It is also US Food and Drug Administration (FDA) approved.
• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global single-chamber pacemaker market report would provide approximately 70 tables, 65 figures, and 184 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product type
• 3.2. Snippet by Indication
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Cardiovascular Diseases
• 4.2. Restraints
  • 4.2.1. Availability of Advanced Alternatives
• 4.3. Opportunity
  • 4.3.1. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Product type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
  • 6.1.2. Market Attractiveness Index, By Product type
• 6.2. Implantable Single-Chamber Pacemakers*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. External Single-Chamber Pacemakers

7. By Indication

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.1.2. Market Attractiveness Index, By Indication
• 7.2. Bradycardia*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Atrial Fibrillation
• 7.4. Heart Block
• 7.5. Sick Sinus Syndrome
• 7.6. Others

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ambulatory Surgical Centers (ASCs)
• 8.4. Cardiac Clinics

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
  • 9.3.7. South America
    • 9.3.7.1. Introduction
    • 9.3.7.2. Key Region-Specific Dynamics
    • 9.3.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
    • 9.3.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.7.6.1. Brazil
    • 9.3.7.6.2. Argentina
    • 9.3.7.6.3. Rest of South America
  • 9.3.8 Asia-Pacific
    • 9.3.8.1 Introduction
    • 9.3.8.2 Key Region-Specific Dynamics
    • 9.3.8.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
    • 9.3.8.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.8.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.8.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.8.6.1 China
    • 9.3.8.6.2 India
    • 9.3.8.6.3 Japan
    • 9.3.8.6.4 South Korea
    • 9.3.8.6.5 Rest of Asia-Pacific
  • 9.3.9 Middle East and Africa
    • 9.3.9.1 Introduction
    • 9.3.9.2 Key Region-Specific Dynamics
    • 9.3.9.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
    • 9.3.9.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.9.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Medtronic*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Boston Scientific Corporation
• 11.3. Abbott Laboratories
• 11.4. Biotronik SE & Co. KG
• 11.5. MicroPort Scientific Corporation
• 11.6. LivaNova PLC
• 11.7. Osypka Medical GmbH
• 11.8. Lepu Medical Technology
• 11.9. Oscor Inc
• 11.10. Shree Pacetronix Ltd

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us